Trust Signals
- Written by the FormBlends Medical Team, reviewed against PubMed literature and FDA approval records.
- Every major claim is graded by evidence type in the ledger table below.
- No financial relationship with any peptide vendor influences this ranking.
- Regulatory and WADA status are noted for each compound.
- Speculation is labeled as such throughout, separate from established data.
Key Takeaways
- Tesamorelin is the only fat-burning peptide with FDA approval (2 mg/day for HIV-related visceral fat) and replicated Phase III human RCT data behind it.
- AOD-9604 completed human trials but failed Phase IIb and Phase III primary endpoints for obesity; its fat-loss effect in humans is not established.
- CJC-1295 plus Ipamorelin is the most widely used research combination, but no published human RCT has tested it specifically for fat loss in healthy adults.
- GLP-1 agonists like semaglutide produce 15 to 17 percent total body weight loss in large RCTs, a magnitude no fat-loss peptide has demonstrated.
- Most peptides sold online as research chemicals have no human purity standard enforcement; HPLC greater than 98 percent with third-party mass spectrometry is the minimum quality bar worth accepting.
What Is the Best Peptide for Fat Burning?
The best peptide for fat burning, judged by actual human trial evidence, is Tesamorelin for visceral fat reduction in the specific population where it was studied. For general fat loss in healthy adults, no single peptide has RCT proof of clinically meaningful effect. CJC-1295 plus Ipamorelin is the most evidence-adjacent protocol, but confidence remains low outside controlled populations.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: All Major Claims Graded
- How Fat-Burning Peptides Work: Mechanism With Numbers
- The Top Peptides for Fat Burning, Ranked by Evidence
- What Most Pages Get Wrong About These Peptides
- Why Storage and Formulation Rules Exist: The Chemistry
- Honest Head-to-Head: Peptides vs. Approved Alternatives
- Label and COA Literacy: How to Judge What You Buy
- Dosing Reference Table
- Side Effects and What the Data Actually Shows
- FAQ
- Sources
Evidence Ledger: All Major Claims Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces visceral fat in HIV lipodystrophy | Multiple Phase III human RCTs (Falutz et al., 2007, 2010) | Positive, replicated | High |
| CJC-1295 raises GH and IGF-1 in humans | Phase I/II human trial (Teichman et al., 2006) | Positive for GH elevation | Moderate |
| CJC-1295 reduces body fat in healthy adults | No published fat-loss RCT in this population | Undemonstrated | Very Low |
| Ipamorelin is selective for GH with low cortisol/prolactin stimulation | Animal studies; one early human pharmacology study | Positive for selectivity | Low |
| AOD-9604 burns fat in humans | Phase IIb and Phase III trials with failed primary endpoints | Not established | Very Low |
| GH stimulates lipolysis via hormone-sensitive lipase | Established endocrine physiology, multiple human studies | Positive | High (mechanism); Low (magnitude via peptide) |
| BPC-157 reduces body fat | No human evidence; animal models only for other endpoints | Not established | Very Low |
| Semaglutide produces clinically meaningful fat loss | Phase III RCT, STEP 1 (Wilding et al., 2021), n=1961 | Strong positive | High |
How Fat-Burning Peptides Work: Mechanism With Numbers
Most peptides marketed for fat loss work through one of two pathways: stimulating growth hormone (GH) release from the pituitary, or mimicking fragments of GH itself.
The GH-Lipolysis Axis
GH binds the GH receptor on adipocytes, activating JAK2-STAT5 signaling, which in turn upregulates hormone-sensitive lipase (HSL) and inhibits lipoprotein lipase activity. The net effect is increased free fatty acid release from stored triglycerides. This mechanism is well-established in human physiology. What is not established is the degree to which a short-acting peptide injection, producing a transient GH pulse, translates into meaningful fat mass change over weeks to months in someone with normal baseline GH.
GHRH Analogs (CJC-1295, Tesamorelin)
Growth hormone-releasing hormone (GHRH) analogs bind the GHRH receptor on pituitary somatotrophs. Teichman et al. (2006) showed CJC-1295 at doses of 30 to 60 mcg/kg increased mean GH levels roughly 2 to 10 fold over baseline and increased IGF-1 by roughly 1.5 to 3 fold in a dose-dependent manner in healthy adults aged 21 to 61. That GH elevation is pharmacologically real. Whether it translates to fat loss in a healthy, well-nourished person without GH deficiency is a separate, unanswered question.
GHRPs and Ghrelin Mimetics (Ipamorelin, GHRP-6, GHRP-2)
These bind the ghrelin receptor (GHS-R1a) on pituitary cells, synergizing with endogenous GHRH to amplify GH pulses. Ipamorelin was characterized in preclinical studies as producing robust GH release with comparatively little effect on cortisol and prolactin compared to GHRP-6 and GHRP-2. GHRP-6 notably stimulates appetite strongly via hypothalamic ghrelin signaling, which directly competes with any fat-loss goal.
AOD-9604 (GH Fragment 176-191)
AOD-9604 is a synthetic fragment of the GH C-terminus that was hypothesized to retain lipolytic activity without the growth-promoting effects of full GH. In rodent models it reduced adiposity. The developer (Monash University / Metabolic Pharmaceuticals) advanced it into human trials. Phase IIb trials did not demonstrate statistically significant weight loss versus placebo. It is now listed as a food ingredient by GRAS notice in some markets, not a drug. The animal-to-human translation did not hold.
The Top Peptides for Fat Burning, Ranked by Evidence
1. Tesamorelin (Strongest Human Evidence)
Tesamorelin is a stabilized GHRH analog (trans-3-hexenoic acid conjugated to GHRH 1-44 amide). The pivotal trials by Falutz and colleagues (2007 New England Journal of Medicine correspondence, then 2010 Lancet Infectious Diseases) enrolled hundreds of HIV-positive patients with lipodystrophy. Treatment at 2 mg/day subcutaneously produced statistically significant reductions in visceral adipose tissue measured by CT scan compared to placebo, with effect sustained at 52 weeks in the extension study. The FDA approved it as Egrifta in 2010. Caveat: these results are in a population with abnormal fat distribution driven by antiretroviral therapy. Extrapolation to healthy adults is speculative.
2. CJC-1295 plus Ipamorelin (Most Used Research Protocol)
This combination stacks a GHRH analog with a GHRP to synergistically amplify GH pulses. The GH elevation is pharmacologically documented for CJC-1295 (Teichman et al., 2006). No fat-loss RCT in healthy adults has been published using this combination. It is the most common protocol discussed in anti-aging and bodybuilding contexts because the mechanistic logic is sound and the individual compounds have human pharmacokinetic data. Confidence in fat loss as an outcome remains very low.
3. Sermorelin
Sermorelin is the first 29 amino acids of GHRH (GHRH 1-29). It was FDA-approved for pediatric GH deficiency diagnosis and is still compounded for adult off-label use. It has the shortest half-life of the GHRH analogs (under 10 minutes). Human trials demonstrated GH stimulation but fat-loss data in adults without GH deficiency is limited to small, uncontrolled studies. More clinical experience exists with sermorelin than with CJC-1295 simply due to its longer history as a compounded medication.
4. AOD-9604
Ranked fourth despite heavy marketing because its human trials failed. Animal data was promising. Human RCT data was not. Its current status as a food ingredient rather than a drug reflects the regulatory outcome of that evidence. Some practitioners still use it, citing the animal mechanism. That is their judgment; the evidentiary confidence is very low.
5. GHRP-2 and GHRP-6 (Lower Selectivity, Practical Disadvantages)
Both stimulate robust GH release. GHRP-6 causes notable hunger and water retention. GHRP-2 raises cortisol and prolactin more than Ipamorelin. For fat loss specifically, elevated cortisol competes directly with lipolysis goals. These are not preferred for fat-burning protocols compared to Ipamorelin.
What Most Pages Get Wrong About These Peptides
This section covers the information commodity pages omit or misrepresent.
1. Confusing GH Elevation With Fat Loss
Every "best peptide" list cites GH elevation as proof of fat burning. GH elevation and fat mass reduction are not the same thing. GH pulses from peptides are real. Whether a transient pulse in a person with normal GH produces detectable fat loss over a standard 12-week protocol, on top of diet and exercise, has not been tested in a controlled human trial for most of these compounds. The mechanism is plausible; the clinical outcome in healthy adults is unproven.
2. The Oral Bioavailability Problem
Peptides are chains of amino acids. The gastrointestinal tract breaks peptide bonds via proteases (pepsin, trypsin, chymotrypsin) before any intact peptide reaches systemic circulation. Oral peptide products, unless using specialized protective technologies (cyclization, nanotechnology encapsulation, or specific non-natural amino acids), deliver negligible bioavailable intact peptide. This applies to most supplements marketed as "peptide complexes." Injectable subcutaneous delivery is why research protocols specify subcutaneous injection, not because it is convenient.
3. Ignoring the Reconstitution Window
Most online discussions focus on dosing but skip the fact that reconstituted peptide solutions degrade. The rate depends on temperature, pH, and the specific peptide sequence, but as a practical rule, reconstituted solutions should be used within 30 days when stored at 2 to 8 degrees Celsius. Agitation, freezing a reconstituted solution, and leaving it at room temperature all accelerate this. A degraded peptide produces no effect and cannot be identified by appearance alone.
4. Citing AOD-9604 Animal Data as Proof
Rodent adiposity models respond to many compounds that fail in humans. AOD-9604 is the textbook case in this peptide space. Citing the rat data after the human trial failure is cherry-picking.
Why Storage and Formulation Rules Exist: The Chemistry
Understanding the chemistry means you can make your own call rather than following a rule blindly.
Why Lyophilized Powder Keeps Longer Than Solution
Hydrolysis and oxidation are the two primary degradation pathways for peptides. Both require water as either a reactant or a medium. Lyophilization removes water, essentially pausing both pathways. When you reconstitute the peptide in bacteriostatic water, you restart the degradation clock. Bacteriostatic water contains 0.9 percent benzyl alcohol as an antimicrobial preservative, which slows microbial growth but does not prevent peptide chemical degradation.
Why Heat Accelerates Degradation
Elevated temperature increases the kinetic energy of molecules, increasing the rate of hydrolysis reactions. This follows Arrhenius kinetics: roughly speaking, every 10 degree Celsius increase approximately doubles reaction rates. Leaving a reconstituted peptide vial at room temperature versus refrigerator temperature meaningfully shortens its usable life.
Why Light Matters for Some Peptides
Peptides containing tryptophan, tyrosine, or phenylalanine residues can undergo photo-oxidation when exposed to UV light. GHRP-6 contains tryptophan (position 4 of its sequence). Store in amber vials or away from direct light as a standard precaution regardless of specific sequence, since you often cannot verify the exact exposure risk of a given lot.
Why Reconstitution Solvent Choice Matters
Never reconstitute injectable peptides with tap water or plain sterile water for multi-dose use. Bacteriostatic water is required for any vial used over multiple days. Acetic acid (0.6 percent) is used as the solvent for some peptides that have poor solubility in neutral pH water. Adding the wrong solvent can cause precipitation or change the ionization state of the peptide, altering its bioactivity. If a peptide does not dissolve with gentle swirling (do not shake), the issue is often pH mismatch with solvent, not impurity.
Honest Head-to-Head: Peptides vs. Approved Alternatives
| Intervention | Human Evidence Level | Fat Loss Magnitude (Human Data) | Regulatory Status (US) | Where Peptide Wins | Where Peptide Loses |
|---|---|---|---|---|---|
| Tesamorelin | Phase III RCT (specific population) | Significant visceral fat reduction in HIV lipodystrophy | FDA-approved (Rx, specific indication) | Visceral fat in specific population; preserves lean mass | Not proven in general obesity; expensive; requires injection |
| CJC-1295 + Ipamorelin | Pharmacokinetic human data; no fat-loss RCT | Not established in controlled trials | Research chemical (not approved for human use) | Theoretical lean body composition effect; lower side-effect profile than exogenous GH | No fat-loss proof; unregulated quality; legal risk |
| Semaglutide (Wegovy) | Multiple Phase III RCTs (STEP program) | Roughly 15 to 17 percent total body weight at 68 weeks (STEP 1, Wilding et al. 2021) | FDA-approved (Rx, obesity indication) | Largest proven fat-loss magnitude of any pharmacotherapy; approved | GI side effects common; weekly injection; cost; some muscle loss |
| Exogenous recombinant GH | Multiple controlled trials | Modest fat reduction; significant side effects at fat-loss doses | FDA-approved (Rx, GH deficiency only) | Stronger GH elevation than peptide stimulation | Suppresses endogenous GH axis; edema; carpal tunnel; cost; prohibited in sport |
| AOD-9604 | Phase IIb/III human trials | Failed to demonstrate significant fat loss vs. placebo | Not approved as drug (GRAS food ingredient in some contexts) | Does not raise IGF-1 (potential safety advantage) | Does not demonstrate fat loss in humans |
The honest conclusion: if the primary goal is fat loss and you are eligible for pharmacotherapy, semaglutide or tirzepatide have far more evidence than any peptide discussed here. If the goal is a research protocol exploring GH-axis modulation with a potentially favorable side-effect profile relative to exogenous GH, Tesamorelin (in its approved population) or CJC-1295/Ipamorelin (with acknowledged very low confidence in fat outcome) are the most defensible choices.
Label and COA Literacy: How to Judge What You Buy
This section applies to any peptide purchased for research purposes. Treat the following as a minimum checklist.
HPLC Purity
High-performance liquid chromatography (HPLC) separates the peptide from impurities by elution time. A result of greater than 98 percent purity means less than 2 percent of the measurable content is not the target peptide. Research-grade standard is typically 98 percent or higher. Some vendors report 95 percent. Below 95 percent is a meaningful concern for unknown impurities.
Mass Spectrometry (MS) Confirmation
HPLC tells you how pure; MS tells you whether the dominant peak is actually the peptide you ordered. A COA with HPLC only and no MS confirmation cannot distinguish a high-purity wrong compound from the correct one. Both methods together are the minimum for injectable research use.
Third-Party Testing
A COA generated by the vendor's own in-house lab has no independence. Look for a named third-party laboratory. If the vendor cannot provide a third-party COA on request, that is a disqualifying flag.
Endotoxin Testing
For injectable peptides, endotoxin contamination (from bacterial cell walls, measured by the Limulus Amebocyte Lysate assay) can cause fever and systemic inflammation. This is separate from purity. Many peptide COAs omit endotoxin testing entirely. Its absence does not mean the product failed; it means the question was never asked.
What a Degraded Product Looks Like
Lyophilized powder should be a white or off-white cake or powder, not discolored brown or yellow. After reconstitution, the solution should be clear and colorless. Cloudiness, particulates, or an amber tint suggest degradation or contamination. Do not use a visually compromised solution.
Dosing Reference Table (Research Protocols; Not Medical Advice)
| Peptide | Common Research Dose | Frequency | Route | Source of Dose Information |
|---|---|---|---|---|
| Tesamorelin | 2 mg | Once daily | Subcutaneous | FDA-approved prescribing information (Egrifta) |
| Sermorelin | 200 to 500 mcg | Once daily (typically at night) | Subcutaneous | Compounding pharmacy protocols; expert consensus |
| CJC-1295 (no DAC) | 100 to 300 mcg | 2 to 3 times daily, pulsatile | Subcutaneous | Derived from Teichman et al. 2006 pharmacokinetic data |
| Ipamorelin | 200 to 300 mcg | 2 to 3 times daily | Subcutaneous | Preclinical and early-phase human pharmacology studies |
| AOD-9604 | 300 to 500 mcg | Once daily (fasted) | Subcutaneous | Protocol from failed clinical trials; not clinically validated |
Side Effects and What the Data Actually Shows
The side-effect data that exists comes primarily from trials in non-healthy populations (GH-deficient patients, HIV patients) or from animal studies. Extrapolation to healthy adults carries uncertainty in both directions, meaning effects could be more or less pronounced.
- Water retention: A common short-term effect of GH elevation. GH promotes sodium and water reabsorption. This can transiently increase the number on a scale and mask fat loss if body composition is not measured properly.
- Transient insulin resistance: GH opposes insulin action. This is a physiological counter-regulatory mechanism. Repeated or sustained GH elevation through peptide use could impair fasting glucose, particularly relevant in pre-diabetic individuals. Monitor with fasting glucose if using long-term protocols.
- Hunger stimulation: GHRP-6 in particular stimulates hypothalamic NPY/AgRP neurons, increasing appetite substantially. This directly counteracts fat loss goals. Ipamorelin is considered more appetite-neutral, though human appetite data for Ipamorelin specifically is sparse.
- Injection site reactions: Erythema, mild swelling, and itching at the injection site are reported with most subcutaneous peptide injections. Rotate injection sites.
- IGF-1 elevation: Sustained GH elevation raises IGF-1. Chronically elevated IGF-1 is associated in epidemiological studies with increased cancer risk, though causality in this context is not established. This is a theoretical concern for long protocols rather than short research use.
Frequently Asked Questions
What is the best peptide for fat burning?
Tesamorelin has the strongest human RCT evidence for reducing visceral fat, specifically in HIV-associated lipodystrophy. For general fat loss in healthy individuals, CJC-1295 plus Ipamorelin is the most commonly used research protocol, though human RCT data outside HIV populations is limited.
Does AOD-9604 actually burn fat in humans?
AOD-9604 showed fat-reduction signals in early human trials but failed to meet primary endpoints in larger Phase IIb and Phase III obesity trials. It is approved as a food ingredient in some markets but not as a fat-loss drug. Confidence in its human fat-burning effect is low.
How do GH-releasing peptides cause fat loss?
GH-releasing peptides stimulate pituitary GH release. Elevated GH activates hormone-sensitive lipase in adipocytes, promoting lipolysis. GH also reduces insulin sensitivity transiently, shifting substrate use toward fat oxidation. The actual fat-loss magnitude in humans depends on baseline GH status, diet, and exercise.
Is CJC-1295 with DAC or without DAC better for fat loss?
CJC-1295 with DAC has a half-life of roughly 6 to 8 days, producing sustained GH elevation. CJC-1295 without DAC (Mod GRF 1-29) has a half-life of roughly 30 minutes and creates a pulsatile GH release more similar to physiological patterns. Neither has been tested in a fat-loss RCT against the other. Most practitioners favor the pulsatile pattern, but this is expert opinion, not trial data.
What dose of Tesamorelin is used for fat loss?
The FDA-approved dose of Tesamorelin (Egrifta) for HIV-associated visceral fat is 2 mg subcutaneously once daily. This dose was used in the pivotal Phase III trials by Falutz et al. (2007, 2010). Using this dose outside its approved indication is off-label.
Can peptides replace a GLP-1 agonist for weight loss?
No. GLP-1 agonists like semaglutide have shown 15 to 17 percent total body weight loss in large RCTs (STEP 1, n=1961). No fat-loss peptide has evidence approaching this magnitude in general obesity. Peptides and GLP-1 agonists work through entirely different mechanisms and are not equivalent alternatives.
How should fat-burning peptides be stored?
Lyophilized peptide powder should be stored at 2 to 8 degrees Celsius before reconstitution and kept away from light. After reconstitution with bacteriostatic water, most peptides degrade meaningfully within 30 days at refrigerator temperature. Heat, repeated freeze-thaw cycles, and agitation all accelerate degradation.
What are the main side effects of GH-releasing peptides?
The most commonly reported side effects are water retention, increased hunger (especially with Ghrelin mimetics like Ipamorelin), transient insulin resistance, and injection site reactions. Long-term GH elevation carries theoretical risks of IGF-1-driven tissue growth. These are research compounds; formal safety data in healthy populations is limited.
Is Ipamorelin a safe peptide for fat loss?
Ipamorelin is considered selective for GH release with less cortisol and prolactin stimulation compared to older GHRPs. Animal studies support this selectivity. However, long-term human safety data is absent. It remains a research compound in most jurisdictions.
Does BPC-157 burn fat?
No credible human evidence supports BPC-157 as a fat-burning peptide. Its studied effects are primarily on wound healing, gut integrity, and tendon repair in animal models. Any fat-loss claims for BPC-157 are speculation extrapolated from indirect metabolic effects.
How do I read a peptide COA to check purity?
Look for HPLC purity reported as a percentage (research-grade typically requires greater than 98 percent), mass spectrometry confirmation of the correct molecular weight, and a third-party lab name. Reject COAs that show only one analytical method, have no date, or come from the same vendor. Endotoxin testing (LAL assay) matters for injectable peptides.
Are fat-burning peptides legal to buy?
Regulatory status varies by country and peptide. Tesamorelin is FDA-approved as a prescription drug for a specific indication. Most other peptides discussed here are sold as research chemicals in the US, meaning they cannot legally be sold for human use. WADA prohibits GH-releasing peptides in competitive sport.
Sources
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. Lancet Infectious Diseases. 2010;10(9):595-603.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- US Food and Drug Administration. Egrifta (tesamorelin) prescribing information. 2010. Available at: fda.gov.
- Johansen PB, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1999
Related peptide guides